Evidence map›Paper›PMID 36801946›Full record

ArticleThe Journal of infectious diseases2023

Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections.

Julio A Huapaya, Jeanette Higgins, Shreya Kanth, Cumhur Y Demirkale, Salina Gairhe, Etsubdink A Aboye, David Regenold, Seynt Jiro Sahagun, Gloria Pastor, Doris Swaim and 20 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04401449 (Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04401449 completednot on this map

Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19)

TypeobservationalSponsorNational Institutes of Health Clinical Center (CC)Ran2020 to 2023Enrolled202ConditionsAcute and Long Term Effects of COVID-19 on Systemic Inflammation, Acute and Long Term Effects of COVID-19 on Lung Function, Acute and Long Term Effects of COVID-19 on Cardiac Function, Acute and Long Term Effects of COVID-19 on Kidney Function
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 6 institutions in 1 country.

Julio A HuapayaCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-8093-4855
Jeanette HigginsApplied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
Shreya KanthCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Cumhur Y DemirkaleCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Salina GairheCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Etsubdink A AboyeMedstar Heart and Vascular Institute, Medstar Washington Hospital Center, Washington, District of Columbia, USA.
David RegenoldCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Seynt Jiro SahagunCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Gloria PastorCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Doris SwaimCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Robin DewarVirus Isolation and Serology Laboratory, Frederick National Laboratory, Applied and Developmental Directorate, Frederick, Maryland, USA.
Tauseef RehmanVirus Isolation and Serology Laboratory, Frederick National Laboratory, Applied and Developmental Directorate, Frederick, Maryland, USA.
Helene C HighbargerVirus Isolation and Serology Laboratory, Frederick National Laboratory, Applied and Developmental Directorate, Frederick, Maryland, USA.
Perrine LallemandVirus Isolation and Serology Laboratory, Frederick National Laboratory, Applied and Developmental Directorate, Frederick, Maryland, USA.
Sylvain LaverdureLaboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory, Applied and Developmental Directorate, Frederick, Maryland, USA.
Joseph AdelsbergerApplied and Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
Adam RupertAIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
Willy LiPharmacy Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Janell KrackPharmacy Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Gebeyehu TeferiUnity Health Care, Washington, District of Columbia, USA.
Janaki KuruppuCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Jeffrey R StrichCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Richard DaveyLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Richard ChildsLaboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Daniel ChertowCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Joseph A KovacsCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Christopher BarnettMedstar Heart and Vascular Institute, Medstar Washington Hospital Center, Washington, District of Columbia, USA.
Parizad Torabi-PariziCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Anthony F SuffrediniCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-4179-0902
COVID-ARC Study Group
National Institutes of Health Clinical Center · USFrederick National Laboratory for Cancer Research · USLeidos (United States) · USNational Institutes of Health · USUniversity of California, San Francisco · USWashington Hospital · US

Funding

Influenza and Emerging Infectious DiseasesZIAAI000984 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DAVEY, RICHARD · 2009 to 2025
$44.1M
Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic PersonsZIACL090062 · CLC · CLINICAL CENTER · PI SUFFREDINI, ANTHONY F. · 2020 to 2025
$0k
6 · The paper itself

Abstract

backgroundData on cellular immune responses in persons with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following vaccination are limited. The evaluation of these patients with SARS-CoV-2 breakthrough infections may provide insight into how vaccinations limit the escalation of deleterious host inflammatory responses.

methodsWe conducted a prospective study of peripheral blood cellular immune responses to SARS-CoV-2 infection in 21 vaccinated patients, all with mild disease, and 97 unvaccinated patients stratified based on disease severity.

resultsWe enrolled 118 persons (aged 50 years [SD 14.5 years], 52 women) with SARS-CoV-2 infection. Compared to unvaccinated patients, vaccinated patients with breakthrough infections had a higher percentage of antigen-presenting monocytes (HLA-DR+), mature monocytes (CD83+), functionally competent T cells (CD127+), and mature neutrophils (CD10+); and lower percentages of activated T cells (CD38+), activated neutrophils (CD64+), and immature B cells (CD127+CD19+). These differences widened with increased disease severity in unvaccinated patients. Longitudinal analysis showed that cellular activation decreased over time but persisted in unvaccinated patients with mild disease at 8-month follow-up.

conclusionsPatients with SARS-CoV-2 breakthrough infections exhibit cellular immune responses that limit the progression of inflammatory responses and suggest mechanisms by which vaccination limits disease severity. These data may have implications for developing more effective vaccines and therapies. Clinical Trials Registration. NCT04401449.

Indexed as

COVID-19Breakthrough InfectionsFemaleHumansProspective StudiesSARS-CoV-2Vaccinationbreakthrough infectionsflow cytometryimmune responseSARS-CoV-2vaccines

Identifiers

PMID36801946
PMCPMC10304754
OpenAlexW4321327274

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.